MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ATAI — AtaiBeckley Inc. Common Stock
NasdaqAtaiBeckley Inc. Common Stock
$7.35
+0.06(+0.82%)
- O
- 7.31
- H
- 7.37
- L
- 7.30
- V
- 9.59M
⏱️ End-of-day dataAs of Sep 10, 2026
Chart
About ATAI
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJun 18, 2021
Employees99
Stock ExchangeNasdaq
Ticker SymbolATAI
Websitehttps://www.ataibeckley.com
Key Financial Statistics
| Market Cap | $2.68B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $3.27 - $7.45 |
| 52-Week Avg Volume | 7.60M |
| VWAP | $7.33 |
| Transactions | 20,859 |
| Total Recorded Bars | 1,316 days |